Skip to main content
Fig. 2 | Trials

Fig. 2

From: Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial

Fig. 2

SPIRIT figure. mRS indicates modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; SAE, serious adverse events. *t−1: directly before randomization, t0: randomization, t1 = directly after randomization; t2 = at 1 h; t3 = at 3 h; t4 = at 24 h; t5 = at 5–7 days or at discharge if earlier; t6 = at 30 days. **Informed consent: as early as deemed possible after IV thrombolysis. ***Administration of IV thrombolytic therapy directly after randomization. ****Neuro-imaging at baseline consists of non-contrast CT, CT-perfusion, and CT-angiography or brain MRI and MRA. Neuro-imaging at 24 h consists preferably of a brain MRI

Back to article page